Poseida Therapeutics, Inc. (PSTX)
Jan 8, 2025 - PSTX was delisted (reason: acquired by Roche)
9.50
0.00 (0.00%)
Inactive · Last trade price
on Jan 7, 2025
Poseida Therapeutics Employees
Poseida Therapeutics had 330 employees as of December 31, 2023. The number of employees increased by 16 or 5.10% compared to the previous year.
Employees
330
Change (1Y)
16
Growth (1Y)
5.10%
Revenue / Employee
$457,145
Profits / Employee
-$184,118
Market Cap
928.85M
Employees Chart
PSTX News
- 13 days ago - Roche to complete acquisition of U.S. biopharma company Poseida - Reuters
- 6 weeks ago - Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting - PRNewsWire
- 7 weeks ago - POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX - Business Wire
- 7 weeks ago - Poseida shares triple on Tuesday, boosted by Roche collaboration - Invezz
- 7 weeks ago - Why This Gene-Therapy Company's Stock Is Rising 228% - Barrons
- 2 months ago - Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details - Benzinga
- 2 months ago - Roche to acquire US-based Poseida Therapeutics - Reuters
- 2 months ago - Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies - GlobeNewsWire